BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.
| Revenue (Most Recent Fiscal Year) | $450.71M |
| Net Income (Most Recent Fiscal Year) | $-88.88M |
| PE Ratio (Current Year Earnings Estimate) | 69.87 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 2.46 |
| Price to Sales Ratio (Trailing 12 Months) | 4.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10.17% |
| Net Margin (Trailing 12 Months) | -10.62% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -11.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.31 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.42 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 209.25M |
| Free Float | 199.21M |
| Market Capitalization | $2.28B |
| Average Volume (Last 20 Days) | 6.69M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 85.88% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |